ATE171069T1 - Transdermale verhütungsmittelformulierung, verfahren und vorrichtung - Google Patents

Transdermale verhütungsmittelformulierung, verfahren und vorrichtung

Info

Publication number
ATE171069T1
ATE171069T1 AT92900228T AT92900228T ATE171069T1 AT E171069 T1 ATE171069 T1 AT E171069T1 AT 92900228 T AT92900228 T AT 92900228T AT 92900228 T AT92900228 T AT 92900228T AT E171069 T1 ATE171069 T1 AT E171069T1
Authority
AT
Austria
Prior art keywords
contraceptive formulation
transdermal contraceptive
transdermal
formulation
progesterone
Prior art date
Application number
AT92900228T
Other languages
English (en)
Inventor
Robert M Gale
Diane E Nedberge
Linda E Atkinson
Original Assignee
Population Council Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Population Council Inc filed Critical Population Council Inc
Application granted granted Critical
Publication of ATE171069T1 publication Critical patent/ATE171069T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Semiconductor Lasers (AREA)
  • Vending Machines For Individual Products (AREA)
  • Steroid Compounds (AREA)
AT92900228T 1990-10-29 1991-10-25 Transdermale verhütungsmittelformulierung, verfahren und vorrichtung ATE171069T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/605,726 US5122382A (en) 1990-10-29 1990-10-29 Transdermal contraceptive formulations, methods and devices

Publications (1)

Publication Number Publication Date
ATE171069T1 true ATE171069T1 (de) 1998-10-15

Family

ID=24424948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900228T ATE171069T1 (de) 1990-10-29 1991-10-25 Transdermale verhütungsmittelformulierung, verfahren und vorrichtung

Country Status (16)

Country Link
US (1) US5122382A (de)
EP (1) EP0577602B1 (de)
JP (1) JP2975684B2 (de)
AT (1) ATE171069T1 (de)
AU (1) AU9041991A (de)
CA (1) CA2088778C (de)
DE (1) DE69130232T2 (de)
DK (1) DK0577602T3 (de)
ES (1) ES2123547T3 (de)
IE (1) IE913741A1 (de)
MX (1) MX9101784A (de)
NO (1) NO303527B1 (de)
NZ (1) NZ240361A (de)
PT (1) PT99340B (de)
WO (1) WO1992007589A1 (de)
ZA (1) ZA918531B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US5256421A (en) * 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
WO1991018570A1 (en) * 1990-06-01 1991-12-12 Robertson, Dale, N. Therapeutically effective topical application of st1435
US5320850A (en) * 1990-10-29 1994-06-14 Alza Corporation Transdermal delivery of the gestogen ST-1435 and devices therefor
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
MX9303557A (es) * 1992-08-06 1994-03-31 Beta Pharm Co Metodo para la administracion de un antiandrogeno, en particular, espironolactona, a traves de la piel.
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
JP3688293B2 (ja) * 1993-09-29 2005-08-24 アルザ・コーポレーション モノグリセリド/乳酸エステル透過促進剤
DE4400770C1 (de) * 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
AU726283B2 (en) * 1995-06-28 2000-11-02 Schering Aktiengesellschaft Pharmaceutical combined preparations, kit and method for hormonal contraception
FR2739032B1 (fr) * 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base d'eva, procede de preparation et utilisation en therapeutique
US5730721A (en) * 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
WO1999032153A1 (en) * 1997-12-22 1999-07-01 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
ES2336054T3 (es) * 1998-12-18 2010-04-07 Alza Corporation Dispositivo transparente para la administracion transdermica de nicotina.
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
AU2003288699A1 (en) * 2002-12-30 2004-07-22 Given Imaging Ltd. Method for in vivo sensing
US20040258742A1 (en) * 2003-04-11 2004-12-23 Van Osdol William Woodson Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク. キラル精製置換ベンゾチアゾールジアミンの合成
WO2009009651A1 (en) * 2007-07-10 2009-01-15 Agile Therapeutics, Inc. Dermal delivery device with ultrasonic weld
US8246978B2 (en) * 2007-07-10 2012-08-21 Agile Therapeutics, Inc. Dermal delivery device with reduced loss of its volatile components
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
CN102753180A (zh) 2009-12-17 2012-10-24 人口委员会股份有限公司 Nestorone*/雌二醇透皮凝胶
EP3513787A1 (de) 2011-01-10 2019-07-24 Invion, Inc Verwendung von beta-adrenergen inversen agonisten zur raucherentwöhnung
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
WO2013177570A1 (en) 2012-05-25 2013-11-28 Terapio Corporation Methods of preventing or treating disease of the central nervous system using rlip76
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3038467B1 (de) 2013-08-13 2020-07-29 Knopp Biosciences LLC Zusammensetzungen und verfahren zur behandlung von plasmazellenerkrankungen und prolymphozytischen b-zellen-erkrankungen
DK3033081T3 (da) 2013-08-13 2021-05-31 Knopp Biosciences Llc Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
WO2015042163A1 (en) 2013-09-17 2015-03-26 Terapio Corporation Methods of preventing or treating mucositis using rlip76

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
CH674618A5 (de) * 1987-04-02 1990-06-29 Ciba Geigy Ag

Also Published As

Publication number Publication date
EP0577602B1 (de) 1998-09-16
CA2088778C (en) 2001-08-14
US5122382A (en) 1992-06-16
NO931209L (no) 1993-04-26
NO303527B1 (no) 1998-07-27
NO931209D0 (no) 1993-03-31
JP2975684B2 (ja) 1999-11-10
EP0577602A1 (de) 1994-01-12
CA2088778A1 (en) 1992-04-30
IE913741A1 (en) 1992-05-22
NZ240361A (en) 1995-07-26
PT99340B (pt) 1999-02-26
WO1992007589A1 (en) 1992-05-14
ZA918531B (en) 1992-08-26
DE69130232D1 (de) 1998-10-22
DE69130232T2 (de) 1999-04-08
DK0577602T3 (da) 1999-06-14
MX9101784A (es) 1992-06-05
JPH06502429A (ja) 1994-03-17
AU9041991A (en) 1992-05-26
ES2123547T3 (es) 1999-01-16
PT99340A (pt) 1992-09-30

Similar Documents

Publication Publication Date Title
ATE171069T1 (de) Transdermale verhütungsmittelformulierung, verfahren und vorrichtung
DE69111352D1 (de) Verfahren und vorrichtung zur ungefähr vertikal ausgerichteten abwicklung von schläuchen.
DE69100162D1 (de) Verfahren und vorrichtung zur reduzierung der emission bei muellverbrennung.
ES2132645T3 (es) Uso en una composicion farmaceutica.
NL192914B (nl) Werkwijze voor de bereiding van een antioxidant preparaat en daarmee verkregen preparaat.
FI950774A0 (fi) Valmiste käytettäväksi 3-ketodesogestreeliä sisältävään transdermaaliseen applikaatioon
ATE293979T1 (de) Pharmazeutische zusammensetzungen enthaltend syntethisch natürliche progesteron und estradiol und verfahren zur herstellung derselben
DE68919194D1 (de) Hydrogenierte Dien-copolymer-Zusammensetzung und Verfahren zu deren Herstellung.
DE69109213D1 (de) Verfahren und Vorrichtung zur Erzeugung von Röntgenstrahlen.
ATE203667T1 (de) Transdermales system in form eines pflasters mit einem tamoxifen-derivat
ATE258068T1 (de) Zusammensetzung, vorrichtung und verfahren zur verbesserten elektrotransport-wirkstoffabgabe
DE68915007D1 (de) Verfahren und Gerät zur Elektronenstrahlbelichtung.
DE59008902D1 (de) Verfahren und Vorrichtung zur Erstellung von medizinischen, insbesondere zahnmedizinischen Prothetik- Passkörpern.
DE68913191D1 (de) Verfahren und vorrichtung zum konditionieren von tabak.
DK0472645T3 (da) Osmotisk doseringsform
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
DE59105635D1 (de) Vorrichtung und verfahren zur materialverdampfung.
NL300004I1 (nl) Voor de behandeling van oestrogeentekorten geschikte samenstelling.
GR900100489A (el) Συνθέσεις χρήσιμοι ως αντισυλληπτικά για άνδρες.
DE69114187D1 (de) Vorrichtung und Verfahren zur Herstellung von Halbleitereinrichtungen.
DE3667537D1 (de) Verfahren zur genauen nachlaufspreizung und sturz an kraftfahrzeugen.
MX9100886A (es) Activador de plasminogeno hibrido,procedimiento para su preparacion y composiciones farmaceuticas que lo contienen
FI923088A0 (fi) Oktadekyl-(2-(n-metylpiperidino)- etyl)-fosfat och foerfarande foer dess framstaellning.
NO931208L (no) Formuleringer for transdermale kontraseptiver, samt fremgangsmaater og innretninger for tilfoersel av slike
ATE141523T1 (de) Spermicides beschichtungsmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time